TruLeaf Medical Expands First-in-Human Clinical Program: Successfully Implants Breakthrough RoseDoc™ Platform via Pure Percutaneous Access
AllMeD Solutions subsidiary demonstrates procedural success in Uzbekistan, building on positive 1-year follow-up data from its initial first-in-human cohort. OR AKIVA, Israel, Oct. 22, 2026 /PRNewswire/ -- AllMeD Solutions, Inc. (TASE: ALMD), a biomedical technology company, today...
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


